Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Senolytic and senomorphic therapies are advancing with compounds like RLS-1496 and α-ESA-me targeting senescent cells. Experts highlight challenges in biomarkers and safety, pushing for personalized ...